Capitalcube gives AngioDynamics, Inc. a score of 34.
Our analysis is based on comparing AngioDynamics, Inc. with the following peers – Merit Medical Systems, Inc., LeMaitre Vascular, Inc., C. R. Bard, Inc., Teleflex Incorporated, ICU Medical, Inc., Boston Scientific Corporation and Johnson & Johnson (MMSI-US, LMAT-US, BCR-US, TFX-US, ICUI-US, BSX-US and JNJ-US).
AngioDynamics, Inc. has a fundamental score of 34 and has a relative valuation of UNDERVALUED.
Access our research and ratings on AngioDynamics, Inc.
- From a peer analysis angle, relative underperformance over the last year has improved more recently.
- It trades at a lower Price/Book multiple (1.21) than its peer median (4.74).
- The market expects faster earnings growth from ANGO-US than from its peers and also a turnaround in its current ROE.
- ANGO-US has relatively low profit margins and median asset efficiency.
- Changes in annual earnings (relative to peers) are better than the change in its revenues (relative to peers), implying the company is focused more on earnings.
- ANGO-US‘s return on assets currently and over the past five years has trailed the peer median and suggests the company might be operationally challenged relative to its peers.
- The company’s relatively low gross and pre-tax margins suggest a non-differentiated product portfolio and not much control on operating costs relative to peers.
- While ANGO-US‘s revenues have increased slower than peer median, the market currently gives the company a higher than peer median P/E ratio and may be factoring in some sort of a strategic play.
- The company’s relatively low level of capital investment and below peer median returns on capital suggest that the company is in maintenance mode.
- ANGO-US has the financial and operating capacity to borrow quickly.
Access our research and ratings on AngioDynamics, Inc.
Leverage & Liquidity
ANGO-US has the financial and operating capacity to borrow quickly.
- With debt at a relatively low 15.97% of its enterprise value compared to an overall benchmark of 25% (Note: The peer median is currently 10.30%), and a well-cushioned interest coverage level of 8.88x, ANGO-US can probably borrow quickly. We classify the company as Quick & Able in terms of its capacity to raise additional debt.
- Of the 7 chosen peers for the company, only 6 of the stocks have an outstanding debt balance. Companies with no debt include LMAT-US.
ANGO-US has maintained its Quick & Able profile from the recent year-end.
- ANGO-US‘s interest coverage is similar to last year’s high of 8.88x, which compares to a low of 4.26x in 2013.
- Compared to 2017, interest coverage has remained relatively stable for both the company (8.88x) and the peer median (12.99x).
- ANGO-US‘s debt-EV is similar to last year’s low of 15.97%, which compares to the 2013 high of 28.50%.
- Though its debt-EV has remained relatively stable at 15.97% compared to 2017, its peer median has decreased to 10.30% from 11.67% during this period.
- Relative to peers, debt-EV rose 1.37 percentage points.
Access the detailed analysis for AngioDynamics, Inc.
Key Liquidity Items
|Company||Debt/Enterprise Value (%)||Current Ratio||Interest Coverage (x)||Cash Flow To Total Debt (%)|
|Merit Medical Systems, Inc.||11.44||2.57||3.75||30.65|
|LeMaitre Vascular, Inc.||0||7.25||1166.86||999|
|C. R. Bard, Inc.||7.05||1.58||17.1||62.86|
|ICU Medical, Inc.||2.3||4.78||101.25||75.65|
|Boston Scientific Corporation||13.45||0.75||5.87||17.49|
|Johnson & Johnson||9.17||1.34||27.52||61.86|
|Best In Class||2.3||7.25||1166.86||999|
Looking for more metrics and analysis for AngioDynamics, Inc.?
AngioDynamics, Inc. engages in the business of medical devices. Its activities include design, manufactures, and sale of medical, surgical and diagnostic devices. The company focuses on devices in the field of vascular access, peripheral vascular, oncology, and surgery. Its product lines include ablation systems, fluid management systems, vascular access products, angiographic products and accessories, drainage products, thrombolytic products and venous products. AngioDynamics was founded by Eamonn P. Hobbs in 1988 and is headquartered in Latham, NY.
The information presented in this report has been obtained from sources deemed to be reliable, but AnalytixInsight does not make any representation about the accuracy, completeness, or timeliness of this information. This report was produced by AnalytixInsight for informational purposes only and nothing contained herein should be construed as an offer to buy or sell or as a solicitation of an offer to buy or sell any security or derivative instrument. This report is current only as of the date that it was published and the opinions, estimates, ratings and other information may change without notice or publication. Past performance is no guarantee of future results. Prior to making an investment or other financial decision, please consult with your financial, legal and tax advisors. AnalytixInsight shall not be liable for any party’s use of this report. AnalytixInsight is not a broker-dealer and does not buy, sell, maintain a position, or make a market in any security referred to herein. One of the principal tenets for us at AnalytixInsight is that the best person to handle your finances is you. By your use of our services or by reading any our reports, you’re agreeing that you bear responsibility for your own investment research and investment decisions. You also agree that AnalytixInsight, its directors, its employees, and its agents will not be liable for any investment decision made or action taken by you and others based on news, information, opinion, or any other material generated by us and/or published through our services. For a complete copy of our disclaimer, please visit our website www.analytixinsight.com.